Rockwell Medical Q2 Sales Rise 11% on New Customers, Guides to $70-75M Revenue
RMTI sits 54% above its 52-week low of $4.885.
Summary
Rockwell Medical reported Q2 net sales of $17.80 million, up 11% year-over-year, driven by new customers in the Western US and higher purchasing from existing accounts. Gross profit jumped 30% to $3.20 million as gross margin expanded to 18% on lower manufacturing costs and higher volume. The company issued full-year 2026 guidance of $70-75 million in net sales, 18-22% gross margin, and $1-2 million adjusted EBITDA. This follows the July 1-for-10 reverse stock split that restored Nasdaq compliance. The slight revenue miss versus consensus ($17.84M) is immaterial; the margin expansion and positive EBITDA outlook are the key positives. Watch for continued customer additions and margin execution in Q3.
At the time of this announcement, RMTI was trading at $7.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.6M. The 52-week trading range was $4.89 to $21.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.